Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
The U.S. Food and Drug Administration (FDA) has given a green light to Titan Pharmaceuticals to begin a first-in-human clinical trial testing an implant that provides continuous release of ropinirole to treat Parkinson’s signs and symptoms. In the open-label Phase 1/2 trial (NCT03250117), which is now recruiting, roughly 20 Parkinson’s…